TC BioPharm Plans Preclinical Study of Potential Monkey Pox Treatment -- Shares Down After Hours-March 2024-www.financetom.com

TC BioPharm Plans Preclinical Study of Potential Monkey Pox Treatment -- Shares Down After Hours

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

TC BioPharm Plans Preclinical Study of Potential Monkey Pox Treatment -- Shares Down After Hours

Sep 6, 2024 1:41 PM

04:23 PM EDT, 09/06/2024 (MT Newswires) -- TC BioPharm ( TCBP ) said Friday it plans to start proof of concept preclinical studies for lead therapeutic TCB 008 for the treatment of monkey pox.

The company said it expects to team up with an infectious disease center or university linked to a similar organization to advance the studies.

TC BioPharm ( TCBP ) shares were down nearly 6% in recent after-hours activity.

Price: 7.40, Change: -0.45, Percent Change: -5.73

Previous page： Carvana Stock Surges On Q3 Earnings: Revenue Beat, EPS Beat, Vehicle Sales Up 34% — 'We Are Just Getting Started' Next page： Markel Group Q3 Earnings, Revenue Rise

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Carvana Stock Surges On Q3 Earnings: Revenue Beat, EPS Beat, Vehicle Sales Up 34% — 'We Are Just Getting Started'

Nov 3, 2024

Carvana Co ( CVNA ) reported financial results for the third quarter after the market close on Wednesday. Here’s a look at the key metrics from the quarter. Q3 Earnings: Carvana ( CVNA ) reported third-quarter revenue of $3.66 billion, beating the consensus estimate of $3.45 billion, according to Benzinga Pro. The used car retailer reported third-quarter earnings of 64 cents per...

Markel Group Q3 Earnings, Revenue Rise

Nov 3, 2024

05:19 PM EDT, 10/30/2024 (MT Newswires) -- Markel Group ( MKL ) reported Q3 earnings late Wednesday of $66.25 per diluted share, up from $3.14 a year earlier. Three analysts polled by Capital IQ expected $24.58. Operating revenue in the quarter ended Sept. 30 rose to $4.61 billion from $3.38 billion a year earlier. Four analysts surveyed by Capital IQ...

DoorDash Q3 Swings to Net Income, Revenue Increases

Nov 3, 2024

04:26 PM EDT, 10/30/2024 (MT Newswires) -- DoorDash ( DASH ) reported Q3 net income late Wednesday of $0.38 per diluted share, swinging from a loss of $0.19 a year earlier. Analysts polled by Capital IQ expected earnings of $0.21. Revenue for the quarter ended Sept. 30 was $2.71 billion, up from $2.16 billion a year earlier. Analysts polled by...

Amgen posts higher profit, obesity data on track for late this year

Nov 3, 2024

Oct 30 (Reuters) - Amgen ( AMGN ) reported a higher-than-expected quarterly profit on Wednesday, driven by a 24% rise in sales of products including cholesterol drug Repatha and Prolia for osteoporosis, and said results of a mid-stage trial of a potentially lucrative obesity medicine will be unveiled late this year. The U.S. biotech company said adjusted third-quarter earnings rose...